Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.63 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.63 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.62 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8433498 | 0.81 | MEN1 (1.00) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL17675194 | 0.81 | MEN1 (0.71) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL28498363 | 0.80 | ATM (0.68) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL29444017 | 0.80 | MEN1 (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL30339171 | 0.80 | MEN1 (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL13162953 | 0.80 | MEN1 (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL27473596 | 0.80 | MEN1 (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL14636633 | 0.80 | MEN1 (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL5225094 | 0.80 | KMT2A (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 | |
| SCHEMBL30362638 | 0.80 | MEN1 (0.69) | MEN1KMT2AKDM4EL3MBTL1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | THE UNIVERSITY OF TOLEDO (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2017223160-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | AIFM1, HSPE1, COX15 | MEN1 67/4885KMT2A 4789/4885KDM4E 3701/4885 |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | AIFM1, HSPE1, COX15 | MEN1 67/4885KMT2A 4789/4885KDM4E 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.